Zanzalintinib (XL092)
Colorectal Cancer
Key Facts
About Exelixis
Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.
View full company profileAbout Exelixis
Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.
View full company profileAbout Exelixis
Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.
View full company profileAbout Exelixis
Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CY-101 + Pembrolizumab | Cytovation | Phase 1/2 |
| M9140 | Merck KGaA | Phase 1/2 |
| Repositioned/Rerouted API | Reponex | Not Specified |
| Leronlimab | CytoDyn | Phase 2 |
| EGFR inhibitor | Acellera | Pre-clinical |
| Cannabics® RCC-33 | CNBX Pharmaceuticals | Preclinical |
| VCR-036 | Vicero Bio | Preclinical |
| CBI-1214 | Cartography Biosciences | Phase 1 |
| QL335 | QLSF Biotherapeutics | Phase 1 |
| Colorectal Cancer Detection Partnership | Daisy Genomics | Research/Assay Development |
| High Internalization ADC | Lytica Therapeutics | Preclinical |
| Undisclosed Colorectal Program(s) | Tavanta Therapeutics | Phase 2 |